Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
NAFLD
Open-data reference.
27 US clinical trials · 9 currently recruiting
Active & Recent Trials
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
Yale University
NCT04634643
Reversal of Lipid-Induced Insulin Resistance
Yale University
NCT02193295
Androgens and NAFLD Longitudinal Cohort Study
University of California, San Francis
NCT06124261
Digoxin In NASH (CODIN)
Yale University
NCT06588699
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
University of Colorado, Denver
NCT05935826
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
Virginia Commonwealth University
NCT05424003
Bicalutamide Therapy in Young Women With NAFLD and PCOS
University of California, San Francis
NCT05979389
NASH AMPK Exercise Dosing (AMPED) Trial
Milton S. Hershey Medical Center
NCT04987879
NAFLD Clinical Care Pathway
VA Office of Research and Development
NCT06671886
Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
University of California, San Francis
NCT04795219
LITMUS Imaging Study
University of Oxford
NCT05479721
Nonalcoholic Fatty Liver Disease in HIV Database
Johns Hopkins University
NCT05023044
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
Hepion Pharmaceuticals
NCT05402371
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Merck Sharp & Dohme
NCT06465186
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
Neuraly
NCT06410924
Accurate Point of Care Liver Disease Diagnostics
University of California, San Diego
NCT05986916
An Imaging-based Quantitative Biomarker Assay for NAFLD in Children
University of Wisconsin, Madison
NCT06354491
The Effects of Glucagon on Hepatic Metabolism
Adrian Vella
NCT05500586
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
University of Iowa
NCT04861571
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05669677
Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE
University of California, Los Angeles
NCT04591106
Healthy Eating Through Reduction Of Excess Sugar
University of Southern California
NCT02948647
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Bird Rock Bio
NCT03261739
The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)
Fred Hutchinson Cancer Center
NCT02663544
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
University of Colorado, Denver
NCT03919929
Healthy Liver - Healthy Brain
University of Texas at Austin
NCT05216796
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
Virginia Commonwealth University
NCT02132780
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the NAFLD Trial Landscape
ClinicalTrials.gov lists 27 US studies indexed under NAFLD, and 9 of those are currently open to recruitment — roughly 33% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for NAFLD shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 9 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for NAFLD is led by Yale University with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 27 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for NAFLD?
PlainTrial tracks 27 US clinical trials for NAFLD, of which 9 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for NAFLD?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.